SIREN : 813908944
MEDIA PHARMA is a French company founded 10 years ago, specialized in the sector Régie publicitaire de médias. Based in MARSEILLE (13006), this company of category PME shows in 2024 a revenue of 20.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 20 010 394 € | 23 658 022 € | 29 246 407 € | 27 873 481 € | 27 936 097 € | N/C | N/C |
| Net income | 269 448 € | 504 845 € | 731 946 € | 474 393 € | 333 157 € | 330 252 € | 420 389 € |
| EBITDA | 306 297 € | 505 955 € | 699 495 € | 578 735 € | 501 368 € | N/C | N/C |
| Net margin | 1.3% | 2.1% | 2.5% | 1.7% | 1.2% | N/C | N/C |
In 2024, MEDIA PHARMA achieves revenue of 20.0 M€. Revenue is declining over the period 2020-2024 (CAGR: -8.0%). Significant drop of -15% vs 2023. After deducting consumption (0 €), gross margin stands at 20.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 306 k€, representing 1.5% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 269 k€, i.e. 1.3% of revenue. This profit can be retained or distributed to shareholders.
20 010 394 €
20 010 394 €
306 297 €
303 705 €
269 448 €
1.5%
The debt ratio (= Financial debt / Equity x 100) stands at 124%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 21%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.7 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 1.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
124.217%
20.632%
1.358%
3.695
40.4%
In 2024, the debt ratio of MEDIA PHARMA (124.22) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of MEDIA PHARMA (20.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of MEDIA PHARMA (3.69) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 121.20. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 4.3x. Financial charges are adequately covered by operations.
121.197
4.342
In 2024, the liquidity ratio of MEDIA PHARMA (121.20) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of MEDIA PHARMA (4.3x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 19 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 20 days. Favorable situation: supplier credit is longer than customer credit by 1 days. Overall, WCR represents 24 days of revenue, i.e. 1.3 M€ to permanently finance.
1 342 297 €
19 j
20 j
0 j
24 j
Indicative estimate only : the number of comparable transactions in this sector is limited (28 transactions). This range of 895 708€ to 3 897 522€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 28 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MEDIA PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Régie publicitaire de médias
The revenue of MEDIA PHARMA in 2024 is 20.0 M€.
Yes, MEDIA PHARMA generated a net profit of 269 k€ in 2024.
The headquarters of MEDIA PHARMA is located in MARSEILLE (13006), in the department Bouches-du-Rhone.
The tax return of MEDIA PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MEDIA PHARMA operates in the sector Régie publicitaire de médias (NAF code 73.12Z). See the 'Sector positioning' section above to compare the company with its competitors.